News Sobi stays on its acquisitive streak with $915m Dova deal Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova
News Sobi cuts staff and buys Novimmune drug in refocus Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
